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Abstract 
Purpose: To review the concomitant use of certain drugs with fruit/vegetable juices that may lead to 
drug-juice interactions resulting in medication-related problems.  
Method: In this systematic review, online databases (PubMed, Google Scholar and Science Direct) 
were searched for information on juices derived from fruits and vegetables that are reported to have 
inhibitory effects on cytochrome P450, p-glycoprotein and organic anion transporting polypeptides 
(OATPs).  
Results: Fruits can inhibit CYP1A1, CYP1A2, CYP1A4, CYP3A1, CYP3A4, CYP2C6, CYP2C9, 
CYP2E1 and drug transporters (P-glycoprotein, OATP). On the other hand CYP1A1, CYP1A2, 
CYP2A2, CYP3A1, CYP1B1, CYP2B1, CYP2B2, CYP2C1, CYP2C6, CYP2E1 can be inhibited by some 
vegetables. Antihypertensives, antidiabetics, statins, analgesics and antipsychotics were the most 
common drugs interacting with fruits and vegetables. The inhibition of their metabolism by fruits and 
vegetables can cause serious toxic effects, e.g., hypertension, poor glycemic control, rhabdomyolosis 
and drug overdose-related toxic effects. Overall, active components of fruits and vegetables can interact 
with many drugs leading to adverse effects.  
Conclusion: Screening of fruits/vegetables for possible risk of interaction, and patient counseling are 
some effective strategies for preventing such interactions for optimal patient care. 
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Drugs are essential components of medical 
therapy but concomitant consumption of other 
substances with drugs can cause unintended 
and unwanted outcomes which may lead to 
significant harm in some cases. The risk of drug 
interactions increases with number of drugs 
being taken by the patient. For example, the risk 
of interactions with 6-10 drugs may just be 7 % 
but with 16-20 drugs, the risk may increase up to 
40 % [1]. High risk patients, such as elderly 
patients taking three or more medications for 
chronic conditions are more susceptible to suffer 
from such interactions. Many of such patients 
also use herbs, fruits, vegetables and other 
nutrients due to their traditional and folk benefits. 
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Nutritional status and diet can affect drug action 
by altering metabolism and function [2]. 
  
The global market of fruits and vegetable juices 
has been forecast to reach 72.29 billion liters by 
the year 2017 due to their therapeutic potential 
[3].  About 42.1 % of US population takes dietary 
supplements and 18.4 % of the population takes 
these supplements with their medications. 
Likewise, 73.1 % of Italian cancer patients take 
their prescribed drugs concomitantly with dietary 
supplements [4].  
 
The concomitant use of multiple drug regimens 
along with different herbs and nutrients makes 
the users more prone to drug-fruit interactions. 
Such interactions can either lead to loss of 
therapeutic efficacy of drug or result in drug 
toxicities e.g. inhibition of metabolism of 
cilostazol by grapefruit juice leads to purpura [2]. 
The various mechanisms by which drug 
interactions can occur are summarized in Figure 
1. 
 
Inhibitory effect of grapefruit on cytochrome P450 
was accidentally discovered when grapefruit 
juice was used to mask the taste of ethanol in 
assessing the effects of alcohol on felodipine. 
Cytochrome P450 is responsible for metabolism of 
several drugs, steroids and carcinogens. The 
members of this family are represented as CYP 
followed by Arabic numeral (family), capital letter 
(subfamily) and Arabic numeral (gene) e.g. 
CYP3A4.  Six enzymes of this family (CYP1A2, 
2C9, 2C19, 2D6, 2E1 and 3A4/5) are responsible 
for 90 % of oxidation processes [5]. Drug efflux 
transporters (e.g. p-glycoprotein) and influx 
transporters (e.g. organic anion transporting 
polypeptide, OATP), located in human intestine 
(enterocytes), are present in several fruit juices. 
OATP is responsible for influx of anionic drugs 
such as HMG CoA reductase inhibitors, 
angiotensin receptor blockers (ARBs), several 
beta blockers and fexofenadine. It has similar 
classification pattern as cytochrome P450 i.e. 
OATP-A and OATP-B in brain and intestine 
respectively. They are further sub-classified as 
OATP1A2 and OATP2B1 [6]. Commonly used 
substrates for CYP450, p-glycoprotein and OATP 
are given in Table 1.  
 
The current review aims to summarize research 
studies investigating general or specific 
interactions between clinically used drugs and 




In a systematic review, interactions of juices 
derived from fruits and vegetables with drugs 
were evaluated using online databases 
(PubMed, GoogleScholar, ScienceDirect). The 
search terms used were grapefruit juice, fruit 
juice-drug interactions, citrus juice drug 
interactions, drug metabolism, drug food 
interactions, p-glycoprotein interactions, tropical 
juice-drug interactions, OATP, cytochrome P450 
drug interactions, vegetable juice drug 
interactions, pharmacodynamics drug 
interactions, pharmacokinetics drug interactions, 
and drug transporters (OATP/p-glycoprotein) 




Figure 1: Types of drug interactions, GIT: Gastrointestinal tract, FPM: First pass metabolism, OATP: Organic 
anion transporting polypeptide 
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Table 1: Commonly used substrates for cytochrome P450, p-glycoprotein and OATP [7,8] 
 














Celecoxib, Diclofenac, Fluoxetine, 
Fluvastatin 



















Macrolides, calcium channel 
blockers, statins, beta 
blockers, anti HIV drugs, 








morphine, digoxin, loperamide, 
cimetidine 
OATP Substrates 
Cephalosporins, anticancer, lipid 
lowering drugs, HIV protease 
inhibitors, ARBs, enalapril, 
valsartan, fexofenadine 





Figure 2: Flow chart of review process 
 
CYP3A4 fruit juices, fruit juice and fruit juices 
warnings,. All studies (in vitro and in vivo) 
demonstrating interactions between drugs and 
juices from fruits and vegetables involving 
inhibition of cytochrome P450 (CYP450), p- 
glycoprotein (p-gp) and organic anion 
transporting polypeptides (OATPs) were included 
in the review. The articles included were those 
published from 1992 to 1013. However, personal 
communications, conference proceedings, un-
published work, drug interactions that do not 
involve CYP450 system methodology adopted 
for the review process. 
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RESULTS AND DISCUSSION 
 
Findings of literature search (Table 2) showed 
that CYP1A1, CYP1A2, CYP1A4, CYP3A1, 
CYP3A4, CYP2C6, CYP2C9 and CYP2E1 are 
more commonly inhibited metabolizing enzymes 
by fruits and their juices. On the other hand 
CYP1A1, CYP1A2, CYP2A2, CYP3A1, CYP1B1, 
CYP2B1, CYP2B2, CYP2C1, CYP2C6, CYP2E1 
were inhibited by vegetables. We found no 
studies demonstrating inhibition of drug 
transporters by tropical fruits and vegetables 
while fruits and their juices caused significant 
inhibition of P-glycoprotein and OATPs in our 
reviewed studies. Fruits and vegetables inhibit 
metabolism of antidiabetics, calcium channel 
blockers and statins resulting in hypoglycemia, 
hypotension and rhabdomyolosis respectively [9–
47]. 
 
Fruits and vegetables are frequently used for 
their nutritional and medicinal potential e.g. use 
of cranberry and mulberry juice for UTIs and 
diabetes respectively [28,32]. Comprehensive 
studies have been conducted to illustrate 
inhibitory effects of temperate fruits on 
cytochrome P450 and drug`s transporters. Limited 
data demonstrate inhibition of such enzymes by 
tropical fruits and vegetables. Moreover, there is 
still paucity of literature explaining the effect of 
tropical fruits and vegetables on drugs 
transporters.  
 
Results from our review showed more frequent 
interactions with temperate fruits as compared to 
tropical fruits and vegetables which might be due 
to extensive research conducted on temperate 
fruit juices as compared to tropical fruits and 
vegetables. CYP3A4 and CYP2C9 are most 
widely inhibited metabolizing enzymes causing 
elevated serum levels in the presence of calcium 
channel blockers, anti-diabetics, warfarin, 
midazolam and diclofenac [9–17,23–34]. Such 
interactions cause toxic effects e.g. 
hypoglycemia with antidiabetics [11–13,18,19] 
and bleeding tendencies with warfarin [23–31]. 
Dahan & Altman reported that inhibition of 
metabolism of statins, felodipine and rapaglinide 
can cause rhabdomyolosis, hypotension and 
hypoglycemia respectively [9]. Both influx and 
efflux drug transporters were significantly 
inhibited by temperate fruit juices. In an earlier 
report, FDA search on adverse events caused by 
concomitant use of grapefruit juice and drugs 
have resulted in identification of 36 potential 
interaction cases. Examples include hypotension 
resulting from calcium channel blockers and 
muscle pain with statins [48,49]. 
Sadeque et al [51] has indicated that inhibition of 
p-glycoprotein causes increases drug delivery 
towards brain. Inhibition of p-glycoprotein by 
grapefruit juice may lead to accumulation of 
loperamide in the brain resulting in respiratory 
depression. Similarly, the inhibition of OATPs by 
apple juice increases bioavailability of 
rosuvastatin resulting in rhabdomyolosis [20,21]. 
Furthermore, fruit juices inhibit metabolizing 
enzymes (CYP450, glucuronosyl transferase), 
drug transporters (OATP, P-gp) and other 
multiple resistance proteins [MRP]. This in turn 
increases plasma levels of drugs metabolized by 
these systems. One widely studied example of 
such inhibition is grapefruit juice which is 
reported to inhibit cytochrome P450, p-
glycoprotein and OATP [9,10]. Even a single 
glass (250 ml) of regular strength grapefruit juice 
can cause potential inhibition of drug 
metabolizing enzymes [9,10]. Inhibition of 
CYP3A4 by grapefruit juice increases the risk of 
toxicity from calcium channel blockers 
(tachycardia, hypotension), statins (myopathy, 
headache, rhabdomyolosis), antihistamines 
(arrhythmias, prolongation of QT intervals) and 
immunosuppressant’s (renal and hepatic 
dysfunction) [52].  
 
The active components of fruits and vegetables 
are involved in inhibition of CYP450 and drug 
transporters. Findings of literature search 
showed that polyphenols [16], disomin [15], 
punicalagin [18], resveratrol [22], qurecetin, 
glycosylated xanthones, mangiferin [23-25], 
bromelin [26] and anthocyanins [34] are 
compounds of fruits and vegetables responsible 
for inhibition of CYP450 and drug transporters. 
 
Although flavonoids (naringenin) and 
furanocoumarins (bergamottin) in fruits and 
vegetables have been reported to inhibit CYP450 
but their protective effect against cardiovascular 
diseases and cancer is known [49].  Moreover, 
there is also potential therapeutic benefit of using 
active constituents of fruits as they increase drug 
bioavailability [53]. Concomitant administration of 
grapefruit juice with cyclosporine is one of the 
examples of drug sparing effect (reduction of 
amount of drug being taken with the help of 
another agent). It reduces repeated dosing of 
cyclosporine leading to reduction in dose-related 
side effects and increase patient compliance. 
Moreover, improvement have been reported in 
efficacy of antihypertensives and anti-psoriosis 
therapy by using grapefruit juice as drug sparing 
agent [53,54]. 
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Table 2: Inhibition of CYP450 and drug transporters by common/temperate fruit juices 
 
Fruit juice Botanical name Interacting system (CYP450/OATP/P-gp) Interacting drug 
Grapefruit juice [9, 10] Citrus paradisi Inhibits CYP3A4, CYP1A2, MRP2, OATP-B, p-
glycoprotein 
CCBs, CNS modulators, HMG CoA reductase, immunosuppressant, 
antiviral, antihistamines, PDE-5 inhibitors, antiarrhythmic drugs and 
several antibiotics 
Seville orange juice [11-
13] 
Citrus aurantium Inhibits p-glycoprotein, CYP3A4, CYP2C9, OATP Fexofenadine, glibenclamide, vinblastine, atenolol, ciprofloxacin, 
levofloxacin, pravastatin, aliskirin, felodipine, montelukast 
Navel & Valencia 
Orange Juice [14]  
Citrus sinensis cv. 
Valencia 
No reported interactions it might be due to 
absence of furanocoumarins 
In vitro and in vivo studies are required to determine its potential of 
drug interactions 
Tangerine juice [15]  Citrus reticulata Inhibits p-glycoprotein, stimulate CYP3A4 
(Disomin in tangerine also inhibit CYP3A4 and 
CYP1A2 in vitro) 
Digoxin, nifedipine (no influence on midazolam pharmacokinetics) 
Lemon juice [16, 17] Citrus limon Inhibits CYP3A4, CYP2C9, possibly OATP 
(because of presence of same polyphenols as in 
grapefruit juice) 
Diclofenac sodium, tolbutamide, glibenclamide and drugs inhibited 
by grape fruit juice 
Lime juice [18, 19] Citrus aurantiifolia Inhibits CYP3A4, CYP2C9 (because of presence 
of same polyphenols as in grapefruit juice) 
Diclofenac sodium, Tolbutamide, possibly glibenclamide, same as 
grapefruit juice, studies are needed for in vivo documentation 
Pomegranate juice [18, 
19] 
Punica granatum Inhibits CYP3A4, CYP2C9, contains punicalagin 
that inhibit intestinal sulfo-conjugation 
Tolbutamide, Possibly carbamazepine (in vitro), other CYP450 
substrates not yet known 
Apple juice [20, 21] Malus domestica Inhibits CYP1A1, OATP family (OATP 1, OATP 
3, NTCP) due to presence of polyphenols 
Estrone-3-sulphate, deltrophin II, fexofenadine, vasopressin, 
rosuvastatin 
Grape juice [22] Vitis vinifera Inhibits CYP3A1, CYP2E1 (due to Resveratrol) Cyclosporin (in vivo), same as red wine 
Mango juice [23-25] Mangifera indica Inhibits CYP1A1, CYP1A2, CYP3A1, CYP2C6, 
CYP2E1, p-glycoprotein (ABCB1) due to 
qurecetin, glycosylated xanthones, mangiferin 
Diclofenac, midazolam, chlorzoxazone, Verapamil, warfarin 
Pineapple juice [26, 27]  Ananas comosus Inhibits CYP2C9 (due to bromelain) Diclofenac, tolbutamide, warfarin & other blood thinners 
Cranberry juice [28-31]  Vaccinium 
macrocarpon 
Inhibits CYP3A4, CYP2C9 Warfarin, CCBs (nifedipine), calcineurin inhibitors, possibly 
diclofenac and fluribiprofen (only in vivo) 
Mulberry juice [32, 33, 17] Morus nigra Inhibits CYP3A1, OATP-B, also modulate (activate) 
CYP3A1 and p-glycoprotein 
Midazolam (in vitro), cyclosporin, further studies are required to 
determine in vivo drug interactions 
Black raspberry juice [34] Rubus coreanus Inhibits CYP3A1, Further studies are required to 
determine interactions of other species of raspberry 
e.g. R. idaeus and R. fruticosus 
Midazolam (in vitro), further studies are required to determine in 
vivo drug interactions 
Blue berry juice [34] Vaccinium 
corymbosum 
Weak inhibitor of CYP3A4 due to anthocyanins In vitro and In vivo studies are needed for documentation 
Guava juice [35, 36] Psidium guajava Weak inhibitor p-glycoprotein, CYP3A4 Midazolam, not well documented, further studies are required for 
p-glycoprotein substrates 
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Table 3: Inhibition of CYP450 and drug transporters by tropical fruit juices 
 
Plum juice [33] Prunus mume No inhibition More in vivo and in vitro studies are 
required 
Kiwi juice [37, 27] Actinidia chinensis Inhibits CYP3A4 Midazolam, diclofenac, tolbutamide 
(no clinically significant interactions 
have reported) 
Pamelo juice 38, 27] Citrus grandis Inhibits CYP2C9, CYP3A4 (no effect 
on P-glycoprotein) 
Diclofenac, tolbutamide, cyclosporine, 
tacrolimus 
Star fruit juice [39] Averrhoa carambola Inhibits CYP3A4 (stronger than grape 
fruit) 
Midazolam, CYP3A4 substrates,  
Passion fruit juice [40, 39, 37] Punica granatum Inhibits CYP2C9, CYP3A4 Midazolam, Diclofenac, Tolbutamide 
(no clinically significant interactions 
have reported) 
Dragon fruit juice [40, 39, 37] Hylocereus undatus Inhibits CYP3A4 Midazolam (no clinically significant 
interactions have been reported) 
Rambutan juice [40, 39, 37] Passiflora 
edulis 
Inhibits CYP3A4 Midazolam (no clinically significant 
interactions have been reported) 
Litchi juice [27] Lichi chinensis Inhibits CYP2C9 Midazolam, Diclofenac 
 
Table 4: Inhibition of CYP450 and drug transporters by vegetable juices fruits 
 
Tomato [41, 42] Lycopersicum esculentum Inhibit CYP1A1, 
CYP1B1, UGP 
N-methyl nitrosourea, 
dimethyl  nitrosamine, 
dimethylhydrazine 
Carrot [43] Dactus carrota Inhibit CYP2E1 Not documented 
Avocado [44] Persea Americana Unknown Warfarin (in vivo) 







Spinach [47] Spinacia oleraceae Inhibit CYP1A2 Heterocyclic aromatic 
amines (in vitro) 
CYP450: cytochrome P450, OATP: organic anion transporting polypeptide, P-gp: p-gylcoprotein, CCBs: calcium channel blockers, CNS: central nervous system, HMG CoA! 
hydroxyl methyl glutaryl coenzyme A, PDE-5: phosphodiesterase type 5, NTCP: sodium taurocholate cotransporting peptide 
 
Mallhi et al 
Trop J Pharm Res, October 2015; 14(10): 1933  
 
Few studies have been conducted on tropical 
fruits and vegetables to elaborate their potential 
in inhibition of metabolizing enzymes and drug 
transporters. Tropical fruits are most commonly 
used in tropical and subtropical countries and 
screening of these fruits can avoid drug related 
complications among patients. More studies are 
required to find out the safety and risk profile of 





As a number of drugs are approved by FDA each 
year, there is less information available about 
their adverse effects and interactions when the 
drugs reach the market. It is imperative for 
physicians and pharmacists to be well aware of 
interactions of drugs with fruits and vegetables 
because such interactions can be more 
complicated than drug–drug interactions.  
Screening of fruits and vegetables for possible 
risk of interactions will ensure success of 
treatment and avoid detrimental effects. 
Fruits/vegetables containing active components 
reported to affect metabolizing enzymes or drug 
transporters must be screened for interactions. It 
will aid health care professionals during patient 
counseling. Since it is difficult to create public 
awareness of the fact that despite offering 
curative and nutritional benefits, fruit juices can 
also confer health risk, and therefore, avoidance 
of concomitant use of fruits/vegetables juices and 
drugs where required, can be an effective 
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